Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4355362 | 0.99 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6356611 | 0.93 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL4349471 | 0.93 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6360692 | 0.91 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6358025 | 0.90 | HTR1A (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6416814 | 0.90 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6362303 | 0.90 | HTR1D (0.53) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL4347602 | 0.88 | HTR1A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6358101 | 0.88 | HTR1A (0.49) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL4348555 | 0.88 | ADRA2A (0.48) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | claimed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | ADRA2A 205/4885ADRA2B 291/4885ADRA2C 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.